Omaha, NE – Streck introduces CD-Chex CD103™ Plus, the only commercially available flow cytometry control that includes CD103, CD30, CD38, CD56, CD138, and Cytoplasmic Lambda in a single control, and the only control on the market to provide reference values for CD138.

The control includes rare leukemia and lymphoma CD markers that are absent in normal whole blood. CD-Chex CD103 Plus provides assayed values for these rare markers, eliminating the need for laboratories to hold and validate patient samples for use as a control.

CD-Chex CD103 Plus offers 30-day open-vial stability and up to 90-day closed-vial stability. It is designed for use on BD Biosciences and Beckman Coulter® flow cytometry systems. This control complements Streck’s full line of flow cytometry controls.

CD-Chex CD103 Plus is For Research Use Only. Not for use in diagnostic procedures.

About Streck, Inc.
Streck is an industry leader in the development and manufacturing of products for clinical and research laboratories. The company’s pursuit of innovative solutions has produced an extensive list of patented products. Streck’s core technology is cell stabilization; product lines support the fields of hematology, immunology and molecular diagnostics. For more information, visit

What we offer

Upcoming Events >